Journal ArticleDOI
Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence
TLDR
In this paper, the authors provide information on the mechanisms of action of ICIs, review the efficacy results of clinical trials using ICIs for TNBC treatment, and assess the side effects of such drugs.About:
This article is published in International Immunopharmacology.The article was published on 2021-06-16. It has received 10 citations till now. The article focuses on the topics: Immune checkpoint & Triple-negative breast cancer.read more
Citations
More filters
Journal ArticleDOI
Black Phosphorus, an Emerging Versatile Nanoplatform for Cancer Immunotherapy.
TL;DR: In this paper, a photothermal agent based on black phosphorus nanosheets (BPNSs) and quantum dots (BPQDs) is proposed for photodynamic therapy (PDT).
Journal ArticleDOI
KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.
A. Rizzo,A. Cusmai,Silvana Acquafredda,Francesco Giovannelli,Luciana Rinaldi,A. Misino,G. Palmiotti +6 more
TL;DR: An overview of recent clinical studies of neoadjuvant immune checkpoint inhibitors in patients with triple-negative breast cancer, especially focusing on the recently presented and published KEYNOTE-522, IMpassion031 and GeparNUEVO trials is provided.
Journal ArticleDOI
Roles of HLA-G/KIR2DL4 in Breast Cancer Immune Microenvironment
Guoxu Zheng,Li Jia,Anderson Yang +2 more
TL;DR: The previous study had shown that HLA-G was a pivotal mediator of breast cancer resistance to trastuzumab, and blockade of the Hla-G/KIR2DL4 interaction can resensitize breast cancer to trastsimab treatment.
Journal ArticleDOI
Oncoinformatic screening of the gene clusters involved in the HER2-positive breast cancer formation along with the in silico pharmacodynamic profiling of selective long-chain omega-3 fatty acids as the metastatic antagonists.
Arwa Morshed,Salauddin Al Azad,Md. Abdur Rashid Mia,M. F. Uddin,T. Ema,Rukaiya Binte Yeasin,Sanjida Ahmed Srishti,Pallab K. Sarker,Rubaita Younus Aurthi,Farhan Jamil,Nure Sharaf Nower Samia,Partha Biswas,Iffat-Ara Sharmeen,Rasel Ahmed,Mahbuba Siddiquy,Nurunnahar +15 more
Journal ArticleDOI
Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes
TL;DR: Over-expressed WT-PD-L1 in human TNBC cells and in luminal-A breast cancer cells demonstrated that cell-autonomous PD-L 1 activities lead to increased tumor cell growth, invasion and release of pro-metastatic factors, which were promoted by PD-1 and were inhibited by mutating S283 in PD- L1.
References
More filters
Journal ArticleDOI
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K. Litton,Hope S. Rugo,Johannes Ettl,Sara A. Hurvitz,Anthony Gonçalves,Kyung Hun Lee,Louis Fehrenbacher,Rinat Yerushalmi,Lida A. Mina,Miguel Martin,Henri Roché,Young-Hyuck Im,Ruben G.W. Quek,Denka Markova,Iulia Cristina Tudor,Alison L. Hannah,Wolfgang Eiermann,Joanne L. Blum +17 more
TL;DR: Among patients with advanced breast cancer and a germline BRCA1/2 mutation, single‐agent talazoparib provided a significant benefit over standard chemotherapy with respect to progression‐free survival.
Journal ArticleDOI
Immune checkpoint inhibitors: recent progress and potential biomarkers.
TL;DR: Different predictive biomarkers for anti-PD-1/PD-L1 and anti-CTLA-4 inhibitors, including immune cells, PD-L 1 overexpression, neoantigens, and genetic and epigenetic signatures are discussed, which could improve the efficacy of this promising new cancer therapy.
Journal ArticleDOI
Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter Schmid,Javier Cortes,Lajos Pusztai,Heather L. McArthur,Sherko Kümmel,Jonas Bergh,Carsten Denkert,Yeon Hee Park,Rina Hui,Nadia Harbeck,Masato Takahashi,Theodoros Foukakis,Peter A. Fasching,Fatima Cardoso,Michael Untch,L. Jia,Vassiliki Karantza,Jing Zhao,Gursel Aktan,Rebecca Dent,Joyce O'Shaughnessy,Keynote Investigators +21 more
TL;DR: Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among thosewho received placebo plusNeoadjuant chemotherapy.
Journal ArticleDOI
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
TL;DR: The status of PD-L1 testing is discussed, emerging data on new biomarker strategies with tumour-infiltrating lymphocytes, mutational burden, immune gene signatures, and multiplex immunohistochemistry are explored, and predictive biomarkers for checkpoint inhibitor-based immunotherapy are explored.
Journal ArticleDOI
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda,Laura Q.M. Chow,Claire Dees,Raanan Berger,Shilpa Gupta,Ravit Geva,Lajos Pusztai,Kumudu Pathiraja,Gursel Aktan,Jonathan D. Cheng,Vassiliki Karantza,Laurence Buisseret +11 more
TL;DR: This phase Ib study describes preliminary evidence of clinical activity and a potentially acceptable safety profile of pembrolizumab given every 2 weeks to patients with heavily pretreated, advanced TNBC.
Related Papers (5)
Triple-Negative Breast Cancer: Immune Modulation as the New Treatment Paradigm
Mary L. Disis,Sasha E. Stanton +1 more
Checkpoint inhibitors in triple‐negative breast cancer (TNBC): Where to go from here
Maryann J. Kwa,Sylvia Adams +1 more